Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
January 14 2013 - 8:20AM
Marketwired
Lost revenues from expiring patents has played a major part in the
Biotech Industry's success in recent years. A total of 676
takeovers of biotechnology and pharmaceutical companies have
occurred in the past three years, with an average premium of 38
percent, according to data collected by Bloomberg. Five Star
Equities examines the outlook for companies in the Biotech Industry
and provides equity research on AEterna Zentaris Inc. (NASDAQ:
AEZS) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).
Access to the full company reports can be found at:
www.FiveStarEquities.com/AEZS www.FiveStarEquities.com/BCRX
At the end of the third quarter five of the biggest drug makers
in the U.S. held over $70 billion in cash, near cash and short-term
investments. Major revenue losses from patent expirations have
forced big pharmaceutical companies to look to biotech companies to
help fill the void. Pfizer's Lipitor and Bristol-Myers' Plavix,
which lost exclusivity in late 2011, had combined annuals revenues
of $17 billion at their peaks.
"We're through many cost-cutting programs, restructurings and
portfolio arrangements," said Henry Gosebruch, Managing Director,
Mergers & Acquisitions J.P. Morgan. "When you put that together
with record levels of cash available and improving, but still
moderate R&D productivity, we think there will be more big
pharma M&A activity in 2013."
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
AEterna Zentaris pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. The
company was recently granted a Special Protocol Assessment for an
upcoming Phase 3 registration trial in endometrial cancer with
AEZS-108. "AEZS-108's innovative targeted approach could offer a
new treatment option for women with endometrial cancer and provide
the Company with a significant market opportunity." stated Juergen
Engel, PhD, President and CEO.
BioCryst designs drug candidates using detailed knowledge of the
structures of active sites of targeted enzymes. The active site of
an enzyme is the area into which a chemical or biological molecule
fits to initiate a biochemical reaction. The company currently has
two late-stage programs: peramivir, a viral neuraminidase inhibitor
for the treatment of influenza, and ulodesine (BCX4208), a purine
nucleoside phosphorylase inhibitor for the treatment of gout.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024